BioSpecifics Technologies Corp. is a biopharmaceutical company that originated and continues to develop, in collaboration with Endo Pharmaceuticals, a specific collagenase formulation, collagenase clostridium histolyticum (CCH). The product was first approved by the FDA in 2010 for the treatment of Dupuytren’s Contracture and was subsequently approved in 2013 for the treatment of Peyronie’s Disease. CCH was licensed to Auxillium Pharmaceuticals (subsequently acquired by Endo Pharmaceuticals) in 2004 and is currently marketed under the brand name XIAFLEX in the US. As a result of royalties received from Endo’s sales, BioSpecifics is a successful, profitable biotechnology company. We have investigated a number of potential further indications for CCH, and in November 2019 Endo announced that its BLA had been accepted for review by the FDA for the treatment of Cellulite.